Aflac Incorporated
- Industria
- Insurance
- Bolsa
- EE. UU.
- País / Región
- USA
- Fecha de salida a bolsa
- 19 de julio de 1984
- Empleados
- 12.716
- Sitio web
- www.aflac.com
Rango de valoración compuesto · conservador $80–$95 / razonable $100–$120 / optimista $130–$150. A $126.56, Entre el rango razonable y el optimista.
Al publicar $117.86 (23 de mayo de 2026)
Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates in two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care, whole life, and GIFT insurance products, as well as WAYS and child endowment, and Tsumitasu insurance products in Japan. Its Aflac U.S. segment provides accident, disability, cancer, critical illness, hospital indemnity, dental, vision, and life insurance products in the United States. The company also provides hearing, final expense, pet, Medicare supplement, supplemental dental and vision, short-term disability, and absence management insurance products, as well as cafeteria plans. It sells its products to individuals, families, and business owners through individual, independent corporate, and affiliated corporate agencies; banks; independent associates/career agents; and brokers. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.
Historia
Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia. Its Aflac Japan operation pioneered Japan's cancer insurance market in 1974. The company completed its IPO on July 19, 1984. Following the deregulation of Japan's market in 2001, more independent cancer and medical insurance providers entered the field. Daniel P. Amos has served as CEO since 1990 and as chairman since 2001.
Posición en el sector
Aflac is a supplemental health and life insurer operating through two segments, Aflac Japan and Aflac U.S. Aflac Japan is the leading provider of cancer and medical insurance by policies in force in Japan and contributed about 53% of adjusted revenue and roughly 69% of pretax adjusted profit in 2025. Its Japan distribution spans about 6,300 sales agencies, roughly 112,000 licensed sales personnel, a Dai-ichi Life partnership covering about 37,000 representatives, Japan Post coverage of about 20,000 post offices, and agreements with about 90% of Japan's banks; the U.S. relies on about 5,300 producing agents and brokers. As of May 22, 2026 its market capitalization was about $60.67 billion, with 12,716 employees. Comparable insurers include Globe Life, MetLife, Prudential, and Unum.
Aún no hay análisis sobre este valor en tu idioma.